



an Open Access Journal by MDPI

NASH and Hepatocellular Carcinoma (HCC)

Guest Editor:

Dr. Feng He

The Center for Cancer Research,
Academy of Integrative Medicine,
Shanghai University of
Traditional Chinese Medicine,
Shanghai, China

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity and metabolic syndrome, is a major cause of liver disease worldwide and its prevalence is increasing in parallel with obesity and type 2 diabetes. This spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis, which ultimately leads to hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide. Liver damage associated with NASH leads to a cycle of cell death, liver regeneration, and fibrosis, during which HCC precursor cells undergo malignant transformation, leading to cancer initiation. Several mechanisms have been proposed to underlie the progression of NASH to cirrhosis, and eventually HCC, including cell death, ER stress, mitochondrial dysfunction, inflammation, and oxidative stress. The mechanisms of progression of NASH, fibrosis, and HCC are far from being understood.

In this Special Issue, we aim to present a series of review and research articles that elucidate the progression in the diagnosis, prevention, and treatment of NASH and HCC, along with the many challenges that still remain.



mdpi.com/si/168742

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI